BioWorld

Nov. 7, 2006

View Archived Issues

Adolor Suffers Setback On FDA Request For More Entereg Data

The FDA delayed approving Adolor Corp.'s Entereg (alvimopan) for postoperative ileus yet again, pending additional safety data, causing the company's shares to tumble by 44.8 percent on Monday. (BioWorld Today) Read More

Biotech Rides Wave Of M&A; Licensing Deals Remain Hot

Read More

Ambit, Cephalon Enter Potential $250M Deal On Kinase Inhibitors

Read More

Abbott Paying $3.7B For Kos In Move To Bolster Lipids Portfolio

Read More

Celgene Raises $1B As Part Of Addition To S&P 500 Index

Read More

Clinic Roundup

Read More

Other News To Note

Read More